Photo private 2015 - Andrew BulpinMake or Break Drug Discovery and Biopharma of Merck Life Science

August 2015, updated November 19/11/15. Merck KGaA is preparing to combine Sigma-Aldrich (SIAL) and Merk Millipore into its new Life Science Division called MilliporeSigma, a denomination which is indicative of Sigma-Aldrich steered by EMD Millipore’s management (see Editor’s note: Merck KGaA: Sigma-Aldrich Acquisition formally completed). The re-structured organisation will retain the three business lines of both organisations which target customers in bioscience, laboratories, and pharma or biotech. Merck and Sigma-Aldrich promise a two-digit growth. How might this be achieved beyond legal completion of the merger?

Merck Millipore’s Process Solutions performs substantially better than SAFC, SIAL’s drug discovery and bioparmaceuticals business. While Merck Millipore has profitably focused on demand in Europe (cp. Martillac, France operations by Merck Biodevelopment), opportunities in Asia have not been satisfactorily exploited compared to competitors until now. Since 2010 when Merck KGaA acquired Millipore the German company has been ranking third in the industry supplying reagents, devices, and services to life sciences. How does that change after the merger? Beyond combining firms, human resources, and operations, which business line will drive growth, and in which region of the world?

Andrew Bulpin, currently Global Head of Merck Millipore Process Solutions, is expected to play a major role in the new Life Science Division In the exclusive interview with B2Bioworld he talks about changes in cell culture media demand, shifts in needs of biopharma customers (e.g. biosimilars versus generics in emerging markets in Asia), as well as ongoing transformation of organisational forms (e.g. in orphan drug manufacturing in Europe).

If you like to read this article, you can purchase it now

Please notice, when purchasing articles you agree to B2Bioworld's Terms and Conditions

Read Now - Please select your license (Prices incl. 7% VAT)

Article free of advertisement - 7 pages
- Includes an assessment of Millipore and SIAL, Process Solutions and SAFC, as well as financials; details on Merck Biodevelopment SAS at Martillac

Full Company License enquire here

Back to section

Related Editorial Articles

Merck: Getting closer to biosimilars markets in Asia and Latin America

Merck Serono Manufacturing: We have biosimilars coming …

Electrophoresis in Proteomics
– Some Common Pitfalls and Smart Ways to Avoid Them

Eurofins: Sustainable profitability – albeit not for investors in a hurry

Dominique Martin to catalyze the French Agency for the Safety of Health Products

TALEs, Zinc Fingers, or Meganucleases
A Practice View from Crop Research and Breeding

Systems Biology In search of good questions
Walter Kolch on the approach taken by Systems Biology Ireland

Corporate Compliance: Training the paper tiger to purr, show its teeth, or jump on
Michael Schulz, former CFO of Bayer CropScience and Compliance Officer

Roche Ethiopia: Build-up of an emerging market

GSK: Stem Cell Research Now and in the Future
Patrick Vallance, today President Pharmaceuticals, R&D of GlaxoSmithKline on company strategy and the the role of cancer stem cells

Metrics for Disease, Health, and Wellness
Personalized medicine? A systems look at human genetic diagnostics and the road ahead for next-generation sequencing by Leroy Hood, Institute for Systems Biology at Seattle

Merck Serono on stem cell research: Clear away complete confusion of terms
Bernhard Kirschbaum, former Head of Global Research and Early Development for Merck Serono on stem cell research

Diagnostic Microfluidics: Sample In – Results Out?
Marc Feiglin, past Chief Technology Officer Life Sciences at Tecan (now at Merck Israel) on strengths and weaknesses of electrowetting development, weaknesses of competitors like Illumina. Prospects of clinical microfluidics